nodes	percent_of_prediction	percent_of_DWPC	metapath
Mebendazole—CYP1A1—breast cancer	0.13	0.461	CbGaD
Mebendazole—TUBB4B—Eribulin—breast cancer	0.102	0.181	CbGbCtD
Mebendazole—TUBB4B—Ixabepilone—breast cancer	0.0979	0.173	CbGbCtD
Mebendazole—TUBA1A—Vinblastine—breast cancer	0.0844	0.149	CbGbCtD
Mebendazole—CYP3A4—breast cancer	0.0831	0.294	CbGaD
Mebendazole—ABCB1—breast cancer	0.0692	0.245	CbGaD
Mebendazole—TUBB4B—Vinorelbine—breast cancer	0.0523	0.0924	CbGbCtD
Mebendazole—TUBB4B—Paclitaxel—breast cancer	0.0367	0.065	CbGbCtD
Mebendazole—TUBB4B—Vinblastine—breast cancer	0.0322	0.057	CbGbCtD
Mebendazole—TUBB4B—Docetaxel—breast cancer	0.0265	0.047	CbGbCtD
Mebendazole—CYP1A1—Toremifene—breast cancer	0.0235	0.0416	CbGbCtD
Mebendazole—ABCB1—Toremifene—breast cancer	0.00919	0.0163	CbGbCtD
Mebendazole—CYP1A1—Tamoxifen—breast cancer	0.00859	0.0152	CbGbCtD
Mebendazole—CYP3A4—Exemestane—breast cancer	0.00794	0.0141	CbGbCtD
Mebendazole—CYP3A4—Letrozole—breast cancer	0.00676	0.012	CbGbCtD
Mebendazole—ABCB1—Lapatinib—breast cancer	0.00671	0.0119	CbGbCtD
Mebendazole—CYP3A4—Anastrozole—breast cancer	0.00602	0.0107	CbGbCtD
Mebendazole—CYP3A4—Toremifene—breast cancer	0.00551	0.00974	CbGbCtD
Mebendazole—CYP3A4—Fulvestrant—breast cancer	0.00512	0.00906	CbGbCtD
Mebendazole—CYP3A4—Thiotepa—breast cancer	0.00456	0.00807	CbGbCtD
Mebendazole—CYP3A4—Ixabepilone—breast cancer	0.00417	0.00738	CbGbCtD
Mebendazole—CYP3A4—Lapatinib—breast cancer	0.00402	0.00711	CbGbCtD
Mebendazole—ABCB1—Vinorelbine—breast cancer	0.00372	0.00658	CbGbCtD
Mebendazole—ABCB1—Tamoxifen—breast cancer	0.00336	0.00594	CbGbCtD
Mebendazole—ABCB1—Mitoxantrone—breast cancer	0.00327	0.00579	CbGbCtD
Mebendazole—CYP3A4—Raloxifene—breast cancer	0.00304	0.00539	CbGbCtD
Mebendazole—ABCB1—Gemcitabine—breast cancer	0.00289	0.00512	CbGbCtD
Mebendazole—ABCB1—Paclitaxel—breast cancer	0.00261	0.00462	CbGbCtD
Mebendazole—ABCB1—Irinotecan—breast cancer	0.00258	0.00456	CbGbCtD
Mebendazole—ABCB1—Vinblastine—breast cancer	0.00229	0.00406	CbGbCtD
Mebendazole—CYP3A4—Vinorelbine—breast cancer	0.00223	0.00394	CbGbCtD
Mebendazole—TUBA1A—mammary gland—breast cancer	0.00208	0.066	CbGeAlD
Mebendazole—CYP3A4—Tamoxifen—breast cancer	0.00201	0.00356	CbGbCtD
Mebendazole—CYP3A4—Mitoxantrone—breast cancer	0.00196	0.00347	CbGbCtD
Mebendazole—ABCB1—Docetaxel—breast cancer	0.00189	0.00334	CbGbCtD
Mebendazole—TUBA1A—nipple—breast cancer	0.00172	0.0546	CbGeAlD
Mebendazole—TUBA1A—Zalcitabine—Gemcitabine—breast cancer	0.00171	0.826	CbGdCrCtD
Mebendazole—CYP3A4—Paclitaxel—breast cancer	0.00157	0.00277	CbGbCtD
Mebendazole—CYP3A4—Irinotecan—breast cancer	0.00154	0.00273	CbGbCtD
Mebendazole—TUBA1A—embryo—breast cancer	0.00142	0.045	CbGeAlD
Mebendazole—ABCB1—Doxorubicin—breast cancer	0.00141	0.00249	CbGbCtD
Mebendazole—TUBB4B—mammary gland—breast cancer	0.00138	0.044	CbGeAlD
Mebendazole—CYP3A4—Vinblastine—breast cancer	0.00137	0.00243	CbGbCtD
Mebendazole—ABCB1—Methotrexate—breast cancer	0.00136	0.00241	CbGbCtD
Mebendazole—TUBA1A—epithelium—breast cancer	0.00116	0.0368	CbGeAlD
Mebendazole—TUBB4B—nipple—breast cancer	0.00114	0.0364	CbGeAlD
Mebendazole—CYP3A4—Docetaxel—breast cancer	0.00113	0.002	CbGbCtD
Mebendazole—TUBA1A—skin of body—breast cancer	0.0011	0.035	CbGeAlD
Mebendazole—TUBA1A—endometrium—breast cancer	0.00104	0.033	CbGeAlD
Mebendazole—Menorrhagia—Goserelin—breast cancer	0.000961	0.0208	CcSEcCtD
Mebendazole—TUBA1A—uterus—breast cancer	0.000955	0.0304	CbGeAlD
Mebendazole—TUBB4B—embryo—breast cancer	0.000944	0.03	CbGeAlD
Mebendazole—TUBA1A—pituitary gland—breast cancer	0.000938	0.0298	CbGeAlD
Mebendazole—TUBA1A—adipose tissue—breast cancer	0.000934	0.0297	CbGeAlD
Mebendazole—Neutropenia—Lapatinib—breast cancer	0.000899	0.0195	CcSEcCtD
Mebendazole—TUBA1A—female reproductive system—breast cancer	0.000859	0.0273	CbGeAlD
Mebendazole—CYP3A4—Doxorubicin—breast cancer	0.000844	0.00149	CbGbCtD
Mebendazole—TUBA1A—adrenal gland—breast cancer	0.000838	0.0266	CbGeAlD
Mebendazole—TUBA1A—bone marrow—breast cancer	0.000811	0.0258	CbGeAlD
Mebendazole—TUBA1A—female gonad—breast cancer	0.000781	0.0248	CbGeAlD
Mebendazole—TUBB4B—skin of body—breast cancer	0.000733	0.0233	CbGeAlD
Mebendazole—TUBA1A—endocrine gland—breast cancer	0.000727	0.0231	CbGeAlD
Mebendazole—Menorrhagia—Mitoxantrone—breast cancer	0.00071	0.0154	CcSEcCtD
Mebendazole—Hepatitis—Fulvestrant—breast cancer	0.000708	0.0153	CcSEcCtD
Mebendazole—TUBB4B—endometrium—breast cancer	0.000691	0.022	CbGeAlD
Mebendazole—Neutropenia—Ixabepilone—breast cancer	0.000678	0.0147	CcSEcCtD
Mebendazole—CYP1A1—nipple—breast cancer	0.000641	0.0204	CbGeAlD
Mebendazole—TUBB4B—uterus—breast cancer	0.000637	0.0202	CbGeAlD
Mebendazole—TUBB4B—pituitary gland—breast cancer	0.000625	0.0199	CbGeAlD
Mebendazole—TUBB4B—adipose tissue—breast cancer	0.000623	0.0198	CbGeAlD
Mebendazole—Hepatitis—Exemestane—breast cancer	0.000615	0.0133	CcSEcCtD
Mebendazole—Neutropenia—Idarubicin—breast cancer	0.000606	0.0131	CcSEcCtD
Mebendazole—TUBB4B—female reproductive system—breast cancer	0.000572	0.0182	CbGeAlD
Mebendazole—Hypersensitivity—Fluoxymesterone—breast cancer	0.000568	0.0123	CcSEcCtD
Mebendazole—Angioedema—Fulvestrant—breast cancer	0.000563	0.0122	CcSEcCtD
Mebendazole—TUBB4B—adrenal gland—breast cancer	0.000558	0.0178	CbGeAlD
Mebendazole—Hepatitis—Letrozole—breast cancer	0.000546	0.0118	CcSEcCtD
Mebendazole—Hepatitis—Anastrozole—breast cancer	0.000546	0.0118	CcSEcCtD
Mebendazole—TUBB4B—bone marrow—breast cancer	0.00054	0.0172	CbGeAlD
Mebendazole—TUBB4B—female gonad—breast cancer	0.000521	0.0166	CbGeAlD
Mebendazole—TUBA1A—lymph node—breast cancer	0.000502	0.016	CbGeAlD
Mebendazole—Neutropenia—Chlorambucil—breast cancer	0.000491	0.0106	CcSEcCtD
Mebendazole—TUBB4B—endocrine gland—breast cancer	0.000484	0.0154	CbGeAlD
Mebendazole—Gastrointestinal pain—Lapatinib—breast cancer	0.000447	0.00969	CcSEcCtD
Mebendazole—Neutropenia—Tamoxifen—breast cancer	0.000437	0.00946	CcSEcCtD
Mebendazole—Albendazole—CYP1A1—breast cancer	0.000436	0.169	CrCbGaD
Mebendazole—Angioedema—Letrozole—breast cancer	0.000435	0.00941	CcSEcCtD
Mebendazole—Angioedema—Anastrozole—breast cancer	0.000435	0.00941	CcSEcCtD
Mebendazole—Abdominal pain—Lapatinib—breast cancer	0.000432	0.00936	CcSEcCtD
Mebendazole—CYP1A1—epithelium—breast cancer	0.000431	0.0137	CbGeAlD
Mebendazole—Neutropenia—Melphalan—breast cancer	0.000428	0.00926	CcSEcCtD
Mebendazole—Gastrointestinal pain—Fulvestrant—breast cancer	0.000411	0.00891	CcSEcCtD
Mebendazole—CYP1A1—skin of body—breast cancer	0.00041	0.013	CbGeAlD
Mebendazole—Hypersensitivity—Lapatinib—breast cancer	0.000403	0.00873	CcSEcCtD
Mebendazole—Agranulocytosis—Vinblastine—breast cancer	0.0004	0.00867	CcSEcCtD
Mebendazole—Urticaria—Fulvestrant—breast cancer	0.0004	0.00865	CcSEcCtD
Mebendazole—Abdominal pain—Fulvestrant—breast cancer	0.000398	0.00861	CcSEcCtD
Mebendazole—Convulsion—Idarubicin—breast cancer	0.000391	0.00847	CcSEcCtD
Mebendazole—Hepatitis—Tamoxifen—breast cancer	0.000374	0.0081	CcSEcCtD
Mebendazole—Neutropenia—Vinorelbine—breast cancer	0.000374	0.00809	CcSEcCtD
Mebendazole—Hypersensitivity—Fulvestrant—breast cancer	0.000371	0.00803	CcSEcCtD
Mebendazole—Hepatitis—Melphalan—breast cancer	0.000366	0.00793	CcSEcCtD
Mebendazole—TUBA1A—Azacitidine—Gemcitabine—breast cancer	0.00036	0.174	CbGdCrCtD
Mebendazole—Gastrointestinal pain—Exemestane—breast cancer	0.000357	0.00774	CcSEcCtD
Mebendazole—Hepatitis—Goserelin—breast cancer	0.000357	0.00773	CcSEcCtD
Mebendazole—CYP1A1—uterus—breast cancer	0.000356	0.0113	CbGeAlD
Mebendazole—CYP1A1—adipose tissue—breast cancer	0.000349	0.0111	CbGeAlD
Mebendazole—Urticaria—Exemestane—breast cancer	0.000347	0.00752	CcSEcCtD
Mebendazole—Abdominal pain—Exemestane—breast cancer	0.000345	0.00748	CcSEcCtD
Mebendazole—Rash—Lapatinib—breast cancer	0.000345	0.00747	CcSEcCtD
Mebendazole—Dermatitis—Lapatinib—breast cancer	0.000345	0.00746	CcSEcCtD
Mebendazole—Gastrointestinal pain—Ixabepilone—breast cancer	0.000337	0.0073	CcSEcCtD
Mebendazole—TUBB4B—lymph node—breast cancer	0.000335	0.0106	CbGeAlD
Mebendazole—Angioedema—Chlorambucil—breast cancer	0.000334	0.00724	CcSEcCtD
Mebendazole—Agranulocytosis—Vinorelbine—breast cancer	0.000332	0.0072	CcSEcCtD
Mebendazole—Abdominal pain—Ixabepilone—breast cancer	0.000326	0.00706	CcSEcCtD
Mebendazole—Hypersensitivity—Exemestane—breast cancer	0.000322	0.00697	CcSEcCtD
Mebendazole—CYP1A1—female reproductive system—breast cancer	0.00032	0.0102	CbGeAlD
Mebendazole—Agranulocytosis—Thiotepa—breast cancer	0.000318	0.00688	CcSEcCtD
Mebendazole—Gastrointestinal pain—Anastrozole—breast cancer	0.000317	0.00687	CcSEcCtD
Mebendazole—Gastrointestinal pain—Letrozole—breast cancer	0.000317	0.00687	CcSEcCtD
Mebendazole—Rash—Fulvestrant—breast cancer	0.000317	0.00687	CcSEcCtD
Mebendazole—Dermatitis—Fulvestrant—breast cancer	0.000317	0.00686	CcSEcCtD
Mebendazole—Convulsion—Chlorambucil—breast cancer	0.000317	0.00686	CcSEcCtD
Mebendazole—Rash—Toremifene—breast cancer	0.000313	0.00678	CcSEcCtD
Mebendazole—Dermatitis—Toremifene—breast cancer	0.000313	0.00677	CcSEcCtD
Mebendazole—Urticaria—Anastrozole—breast cancer	0.000308	0.00668	CcSEcCtD
Mebendazole—Urticaria—Letrozole—breast cancer	0.000308	0.00668	CcSEcCtD
Mebendazole—Neutropenia—Irinotecan—breast cancer	0.000308	0.00667	CcSEcCtD
Mebendazole—Neutropenia—Mitoxantrone—breast cancer	0.000308	0.00667	CcSEcCtD
Mebendazole—Ketorolac—PTGS1—breast cancer	0.000307	0.119	CrCbGaD
Mebendazole—Abdominal pain—Letrozole—breast cancer	0.000307	0.00665	CcSEcCtD
Mebendazole—Abdominal pain—Anastrozole—breast cancer	0.000307	0.00665	CcSEcCtD
Mebendazole—Hypersensitivity—Ixabepilone—breast cancer	0.000304	0.00658	CcSEcCtD
Mebendazole—Gastrointestinal pain—Raloxifene—breast cancer	0.000301	0.00652	CcSEcCtD
Mebendazole—Gastrointestinal pain—Idarubicin—breast cancer	0.000301	0.00652	CcSEcCtD
Mebendazole—Neutropenia—Gemcitabine—breast cancer	0.0003	0.0065	CcSEcCtD
Mebendazole—Angioedema—Tamoxifen—breast cancer	0.000297	0.00644	CcSEcCtD
Mebendazole—Urticaria—Idarubicin—breast cancer	0.000293	0.00634	CcSEcCtD
Mebendazole—CYP1A1—female gonad—breast cancer	0.000292	0.00927	CbGeAlD
Mebendazole—Abdominal pain—Idarubicin—breast cancer	0.000291	0.00631	CcSEcCtD
Mebendazole—Abdominal pain—Raloxifene—breast cancer	0.000291	0.00631	CcSEcCtD
Mebendazole—Convulsion—Vinblastine—breast cancer	0.00029	0.00629	CcSEcCtD
Mebendazole—Hypersensitivity—Anastrozole—breast cancer	0.000286	0.00619	CcSEcCtD
Mebendazole—Albendazole—CYP3A4—breast cancer	0.000279	0.108	CrCbGaD
Mebendazole—Convulsion—Melphalan—breast cancer	0.000276	0.00598	CcSEcCtD
Mebendazole—Rash—Exemestane—breast cancer	0.000275	0.00597	CcSEcCtD
Mebendazole—Dermatitis—Exemestane—breast cancer	0.000275	0.00596	CcSEcCtD
Mebendazole—ABCB1—embryo—breast cancer	0.000275	0.00873	CbGeAlD
Mebendazole—Agranulocytosis—Mitoxantrone—breast cancer	0.000274	0.00594	CcSEcCtD
Mebendazole—Hypersensitivity—Idarubicin—breast cancer	0.000271	0.00588	CcSEcCtD
Mebendazole—CYP1A1—endocrine gland—breast cancer	0.000271	0.00862	CbGeAlD
Mebendazole—Convulsion—Goserelin—breast cancer	0.000269	0.00583	CcSEcCtD
Mebendazole—Agranulocytosis—Gemcitabine—breast cancer	0.000267	0.00579	CcSEcCtD
Mebendazole—Hepatitis—Mitoxantrone—breast cancer	0.000264	0.00571	CcSEcCtD
Mebendazole—Agranulocytosis—Fluorouracil—breast cancer	0.000263	0.00569	CcSEcCtD
Mebendazole—Rash—Ixabepilone—breast cancer	0.00026	0.00563	CcSEcCtD
Mebendazole—Dermatitis—Ixabepilone—breast cancer	0.00026	0.00562	CcSEcCtD
Mebendazole—Angioedema—Vinorelbine—breast cancer	0.000254	0.00551	CcSEcCtD
Mebendazole—Neutropenia—Paclitaxel—breast cancer	0.000251	0.00544	CcSEcCtD
Mebendazole—Tiaprofenic acid—PTGS1—breast cancer	0.000251	0.0968	CrCbGaD
Mebendazole—Rash—Anastrozole—breast cancer	0.000245	0.0053	CcSEcCtD
Mebendazole—Rash—Letrozole—breast cancer	0.000245	0.0053	CcSEcCtD
Mebendazole—Dermatitis—Anastrozole—breast cancer	0.000245	0.0053	CcSEcCtD
Mebendazole—Dermatitis—Letrozole—breast cancer	0.000245	0.0053	CcSEcCtD
Mebendazole—Gastrointestinal pain—Chlorambucil—breast cancer	0.000244	0.00528	CcSEcCtD
Mebendazole—Nepafenac—PTGS1—breast cancer	0.000238	0.0921	CrCbGaD
Mebendazole—Urticaria—Chlorambucil—breast cancer	0.000237	0.00513	CcSEcCtD
Mebendazole—Abdominal pain—Chlorambucil—breast cancer	0.000236	0.00511	CcSEcCtD
Mebendazole—CYP3A4—female reproductive system—breast cancer	0.000235	0.00748	CbGeAlD
Mebendazole—Rash—Raloxifene—breast cancer	0.000232	0.00503	CcSEcCtD
Mebendazole—Rash—Idarubicin—breast cancer	0.000232	0.00503	CcSEcCtD
Mebendazole—Dermatitis—Raloxifene—breast cancer	0.000232	0.00503	CcSEcCtD
Mebendazole—Dermatitis—Idarubicin—breast cancer	0.000232	0.00503	CcSEcCtD
Mebendazole—Albendazole—ABCB1—breast cancer	0.000232	0.0896	CrCbGaD
Mebendazole—Convulsion—Thiotepa—breast cancer	0.00023	0.00499	CcSEcCtD
Mebendazole—ABCB1—epithelium—breast cancer	0.000224	0.00712	CbGeAlD
Mebendazole—Gastrointestinal pain—Vinblastine—breast cancer	0.000224	0.00484	CcSEcCtD
Mebendazole—Hypersensitivity—Chlorambucil—breast cancer	0.00022	0.00476	CcSEcCtD
Mebendazole—Gastrointestinal pain—Tamoxifen—breast cancer	0.000217	0.0047	CcSEcCtD
Mebendazole—Abdominal pain—Vinblastine—breast cancer	0.000216	0.00468	CcSEcCtD
Mebendazole—Neutropenia—Docetaxel—breast cancer	0.000213	0.00461	CcSEcCtD
Mebendazole—Urticaria—Tamoxifen—breast cancer	0.000211	0.00457	CcSEcCtD
Mebendazole—Abdominal pain—Tamoxifen—breast cancer	0.00021	0.00455	CcSEcCtD
Mebendazole—Gastrointestinal pain—Goserelin—breast cancer	0.000207	0.00449	CcSEcCtD
Mebendazole—Urticaria—Melphalan—breast cancer	0.000207	0.00448	CcSEcCtD
Mebendazole—Neutropenia—Capecitabine—breast cancer	0.000206	0.00447	CcSEcCtD
Mebendazole—Urticaria—Goserelin—breast cancer	0.000202	0.00437	CcSEcCtD
Mebendazole—Hypersensitivity—Vinblastine—breast cancer	0.000201	0.00436	CcSEcCtD
Mebendazole—ABCB1—endometrium—breast cancer	0.000201	0.00639	CbGeAlD
Mebendazole—Abdominal pain—Goserelin—breast cancer	0.000201	0.00434	CcSEcCtD
Mebendazole—CYP3A4—endocrine gland—breast cancer	0.000199	0.00633	CbGeAlD
Mebendazole—Convulsion—Mitoxantrone—breast cancer	0.000199	0.00431	CcSEcCtD
Mebendazole—Hypersensitivity—Tamoxifen—breast cancer	0.000196	0.00424	CcSEcCtD
Mebendazole—Hypersensitivity—Melphalan—breast cancer	0.000192	0.00415	CcSEcCtD
Mebendazole—Convulsion—Fluorouracil—breast cancer	0.000191	0.00413	CcSEcCtD
Mebendazole—Agranulocytosis—Docetaxel—breast cancer	0.00019	0.00411	CcSEcCtD
Mebendazole—Ketoprofen—CXCL8—breast cancer	0.000189	0.0731	CrCbGaD
Mebendazole—CYP1A1—lymph node—breast cancer	0.000187	0.00596	CbGeAlD
Mebendazole—Hypersensitivity—Goserelin—breast cancer	0.000187	0.00405	CcSEcCtD
Mebendazole—Gastrointestinal pain—Vinorelbine—breast cancer	0.000186	0.00402	CcSEcCtD
Mebendazole—ABCB1—uterus—breast cancer	0.000185	0.00589	CbGeAlD
Mebendazole—Agranulocytosis—Capecitabine—breast cancer	0.000184	0.00397	CcSEcCtD
Mebendazole—Hepatitis—Docetaxel—breast cancer	0.000182	0.00395	CcSEcCtD
Mebendazole—ABCB1—pituitary gland—breast cancer	0.000182	0.00578	CbGeAlD
Mebendazole—ABCB1—adipose tissue—breast cancer	0.000181	0.00576	CbGeAlD
Mebendazole—Urticaria—Vinorelbine—breast cancer	0.000181	0.00391	CcSEcCtD
Mebendazole—Abdominal pain—Vinorelbine—breast cancer	0.00018	0.00389	CcSEcCtD
Mebendazole—Gastrointestinal pain—Thiotepa—breast cancer	0.000177	0.00384	CcSEcCtD
Mebendazole—Hepatitis—Capecitabine—breast cancer	0.000177	0.00382	CcSEcCtD
Mebendazole—Ketorolac—PTGS2—breast cancer	0.000176	0.0679	CrCbGaD
Mebendazole—Urticaria—Thiotepa—breast cancer	0.000172	0.00373	CcSEcCtD
Mebendazole—Abdominal pain—Thiotepa—breast cancer	0.000172	0.00372	CcSEcCtD
Mebendazole—Angioedema—Paclitaxel—breast cancer	0.000171	0.00371	CcSEcCtD
Mebendazole—Rash—Tamoxifen—breast cancer	0.000167	0.00363	CcSEcCtD
Mebendazole—Hypersensitivity—Vinorelbine—breast cancer	0.000167	0.00363	CcSEcCtD
Mebendazole—Dermatitis—Tamoxifen—breast cancer	0.000167	0.00362	CcSEcCtD
Mebendazole—ABCB1—female reproductive system—breast cancer	0.000166	0.00529	CbGeAlD
Mebendazole—Rash—Melphalan—breast cancer	0.000164	0.00355	CcSEcCtD
Mebendazole—Dermatitis—Melphalan—breast cancer	0.000164	0.00355	CcSEcCtD
Mebendazole—ABCB1—adrenal gland—breast cancer	0.000162	0.00516	CbGeAlD
Mebendazole—Convulsion—Paclitaxel—breast cancer	0.000162	0.00351	CcSEcCtD
Mebendazole—Rash—Goserelin—breast cancer	0.00016	0.00346	CcSEcCtD
Mebendazole—Hypersensitivity—Thiotepa—breast cancer	0.00016	0.00346	CcSEcCtD
Mebendazole—Dermatitis—Goserelin—breast cancer	0.00016	0.00346	CcSEcCtD
Mebendazole—ABCB1—bone marrow—breast cancer	0.000157	0.005	CbGeAlD
Mebendazole—Neutropenia—Methotrexate—breast cancer	0.000154	0.00333	CcSEcCtD
Mebendazole—Gastrointestinal pain—Irinotecan—breast cancer	0.000153	0.00332	CcSEcCtD
Mebendazole—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000153	0.00332	CcSEcCtD
Mebendazole—ABCB1—female gonad—breast cancer	0.000151	0.00482	CbGeAlD
Mebendazole—Urticaria—Mitoxantrone—breast cancer	0.000149	0.00322	CcSEcCtD
Mebendazole—Abdominal pain—Mitoxantrone—breast cancer	0.000148	0.00321	CcSEcCtD
Mebendazole—Abdominal pain—Irinotecan—breast cancer	0.000148	0.00321	CcSEcCtD
Mebendazole—Neutropenia—Epirubicin—breast cancer	0.000144	0.00311	CcSEcCtD
Mebendazole—Tiaprofenic acid—PTGS2—breast cancer	0.000143	0.0553	CrCbGaD
Mebendazole—Rash—Vinorelbine—breast cancer	0.000143	0.0031	CcSEcCtD
Mebendazole—Dermatitis—Vinorelbine—breast cancer	0.000143	0.0031	CcSEcCtD
Mebendazole—Urticaria—Fluorouracil—breast cancer	0.000143	0.00309	CcSEcCtD
Mebendazole—ABCB1—endocrine gland—breast cancer	0.000141	0.00448	CbGeAlD
Mebendazole—Hypersensitivity—Mitoxantrone—breast cancer	0.000138	0.00299	CcSEcCtD
Mebendazole—Hypersensitivity—Irinotecan—breast cancer	0.000138	0.00299	CcSEcCtD
Mebendazole—Convulsion—Docetaxel—breast cancer	0.000138	0.00298	CcSEcCtD
Mebendazole—Rash—Thiotepa—breast cancer	0.000137	0.00296	CcSEcCtD
Mebendazole—Dermatitis—Thiotepa—breast cancer	0.000137	0.00296	CcSEcCtD
Mebendazole—Agranulocytosis—Methotrexate—breast cancer	0.000137	0.00296	CcSEcCtD
Mebendazole—Nepafenac—PTGS2—breast cancer	0.000136	0.0526	CrCbGaD
Mebendazole—Neutropenia—Doxorubicin—breast cancer	0.000133	0.00288	CcSEcCtD
Mebendazole—Hypersensitivity—Fluorouracil—breast cancer	0.000132	0.00286	CcSEcCtD
Mebendazole—Hepatitis—Methotrexate—breast cancer	0.000131	0.00285	CcSEcCtD
Mebendazole—Agranulocytosis—Epirubicin—breast cancer	0.000128	0.00277	CcSEcCtD
Mebendazole—Gastrointestinal pain—Paclitaxel—breast cancer	0.000125	0.00271	CcSEcCtD
Mebendazole—Hepatitis—Epirubicin—breast cancer	0.000123	0.00266	CcSEcCtD
Mebendazole—Urticaria—Paclitaxel—breast cancer	0.000121	0.00263	CcSEcCtD
Mebendazole—Abdominal pain—Paclitaxel—breast cancer	0.000121	0.00262	CcSEcCtD
Mebendazole—Agranulocytosis—Doxorubicin—breast cancer	0.000118	0.00256	CcSEcCtD
Mebendazole—Rash—Irinotecan—breast cancer	0.000118	0.00256	CcSEcCtD
Mebendazole—Rash—Mitoxantrone—breast cancer	0.000118	0.00256	CcSEcCtD
Mebendazole—Dermatitis—Mitoxantrone—breast cancer	0.000118	0.00256	CcSEcCtD
Mebendazole—Dermatitis—Irinotecan—breast cancer	0.000118	0.00256	CcSEcCtD
Mebendazole—Rash—Gemcitabine—breast cancer	0.000115	0.00249	CcSEcCtD
Mebendazole—Dermatitis—Gemcitabine—breast cancer	0.000115	0.00249	CcSEcCtD
Mebendazole—Hepatitis—Doxorubicin—breast cancer	0.000114	0.00246	CcSEcCtD
Mebendazole—Rash—Fluorouracil—breast cancer	0.000113	0.00245	CcSEcCtD
Mebendazole—Dermatitis—Fluorouracil—breast cancer	0.000113	0.00245	CcSEcCtD
Mebendazole—Hypersensitivity—Paclitaxel—breast cancer	0.000113	0.00244	CcSEcCtD
Mebendazole—Gastrointestinal pain—Docetaxel—breast cancer	0.000106	0.00229	CcSEcCtD
Mebendazole—Gastrointestinal pain—Capecitabine—breast cancer	0.000103	0.00222	CcSEcCtD
Mebendazole—Abdominal pain—Docetaxel—breast cancer	0.000102	0.00222	CcSEcCtD
Mebendazole—Urticaria—Capecitabine—breast cancer	9.96e-05	0.00216	CcSEcCtD
Mebendazole—Abdominal pain—Capecitabine—breast cancer	9.92e-05	0.00215	CcSEcCtD
Mebendazole—Convulsion—Methotrexate—breast cancer	9.91e-05	0.00215	CcSEcCtD
Mebendazole—ABCB1—lymph node—breast cancer	9.74e-05	0.0031	CbGeAlD
Mebendazole—Ketoprofen—PTGS1—breast cancer	9.66e-05	0.0373	CrCbGaD
Mebendazole—Rash—Paclitaxel—breast cancer	9.64e-05	0.00209	CcSEcCtD
Mebendazole—Dermatitis—Paclitaxel—breast cancer	9.63e-05	0.00209	CcSEcCtD
Mebendazole—Hypersensitivity—Docetaxel—breast cancer	9.54e-05	0.00207	CcSEcCtD
Mebendazole—Convulsion—Epirubicin—breast cancer	9.28e-05	0.00201	CcSEcCtD
Mebendazole—Hypersensitivity—Capecitabine—breast cancer	9.24e-05	0.002	CcSEcCtD
Mebendazole—Convulsion—Doxorubicin—breast cancer	8.58e-05	0.00186	CcSEcCtD
Mebendazole—Rash—Docetaxel—breast cancer	8.17e-05	0.00177	CcSEcCtD
Mebendazole—Dermatitis—Docetaxel—breast cancer	8.16e-05	0.00177	CcSEcCtD
Mebendazole—Rash—Capecitabine—breast cancer	7.91e-05	0.00171	CcSEcCtD
Mebendazole—Dermatitis—Capecitabine—breast cancer	7.9e-05	0.00171	CcSEcCtD
Mebendazole—Gastrointestinal pain—Methotrexate—breast cancer	7.64e-05	0.00165	CcSEcCtD
Mebendazole—Urticaria—Methotrexate—breast cancer	7.42e-05	0.00161	CcSEcCtD
Mebendazole—Abdominal pain—Methotrexate—breast cancer	7.38e-05	0.0016	CcSEcCtD
Mebendazole—Gastrointestinal pain—Epirubicin—breast cancer	7.15e-05	0.00155	CcSEcCtD
Mebendazole—Urticaria—Epirubicin—breast cancer	6.94e-05	0.0015	CcSEcCtD
Mebendazole—Abdominal pain—Epirubicin—breast cancer	6.91e-05	0.0015	CcSEcCtD
Mebendazole—Hypersensitivity—Methotrexate—breast cancer	6.88e-05	0.00149	CcSEcCtD
Mebendazole—Gastrointestinal pain—Doxorubicin—breast cancer	6.61e-05	0.00143	CcSEcCtD
Mebendazole—Hypersensitivity—Epirubicin—breast cancer	6.44e-05	0.00139	CcSEcCtD
Mebendazole—Urticaria—Doxorubicin—breast cancer	6.42e-05	0.00139	CcSEcCtD
Mebendazole—Abdominal pain—Doxorubicin—breast cancer	6.39e-05	0.00138	CcSEcCtD
Mebendazole—Hypersensitivity—Doxorubicin—breast cancer	5.96e-05	0.00129	CcSEcCtD
Mebendazole—Rash—Methotrexate—breast cancer	5.89e-05	0.00128	CcSEcCtD
Mebendazole—Dermatitis—Methotrexate—breast cancer	5.88e-05	0.00127	CcSEcCtD
Mebendazole—Ketoprofen—PTGS2—breast cancer	5.52e-05	0.0213	CrCbGaD
Mebendazole—Rash—Epirubicin—breast cancer	5.51e-05	0.00119	CcSEcCtD
Mebendazole—Dermatitis—Epirubicin—breast cancer	5.5e-05	0.00119	CcSEcCtD
Mebendazole—Rash—Doxorubicin—breast cancer	5.1e-05	0.0011	CcSEcCtD
Mebendazole—Dermatitis—Doxorubicin—breast cancer	5.09e-05	0.0011	CcSEcCtD
Mebendazole—Ketoprofen—ALB—breast cancer	4.92e-05	0.019	CrCbGaD
Mebendazole—CYP3A4—Metabolism—SYNJ2—breast cancer	7.8e-06	0.000112	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—breast cancer	7.78e-06	0.000111	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—breast cancer	7.76e-06	0.000111	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CA9—breast cancer	7.74e-06	0.000111	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTA4—breast cancer	7.74e-06	0.000111	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—breast cancer	7.7e-06	0.00011	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—breast cancer	7.65e-06	0.000109	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ALDH7A1—breast cancer	7.59e-06	0.000109	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ALDH1A1—breast cancer	7.59e-06	0.000109	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTA2—breast cancer	7.55e-06	0.000108	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GPX2—breast cancer	7.55e-06	0.000108	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—breast cancer	7.53e-06	0.000108	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—breast cancer	7.51e-06	0.000107	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GPX4—breast cancer	7.45e-06	0.000107	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SULT1A1—breast cancer	7.45e-06	0.000107	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—breast cancer	7.35e-06	0.000105	CbGpPWpGaD
Mebendazole—TUBB4B—Cell Cycle—TP53—breast cancer	7.3e-06	0.000104	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—IDH1—breast cancer	7.28e-06	0.000104	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTA1—breast cancer	7.28e-06	0.000104	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—FHL2—breast cancer	7.27e-06	0.000104	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PHGDH—breast cancer	7.27e-06	0.000104	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NME1—breast cancer	7.27e-06	0.000104	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ADSL—breast cancer	7.27e-06	0.000104	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—UMPS—breast cancer	7.27e-06	0.000104	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NDUFS3—breast cancer	7.25e-06	0.000104	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—NCOA1—breast cancer	7.24e-06	0.000104	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NAT2—breast cancer	7.2e-06	0.000103	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—BRIP1—breast cancer	7.13e-06	0.000102	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—HPSE—breast cancer	7.13e-06	0.000102	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—LDHB—breast cancer	7.13e-06	0.000102	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—PLG—breast cancer	7.05e-06	0.000101	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—breast cancer	6.96e-06	9.96e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CHST9—breast cancer	6.82e-06	9.76e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—breast cancer	6.78e-06	9.7e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—HMMR—breast cancer	6.76e-06	9.67e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTA3—breast cancer	6.76e-06	9.67e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ABCC1—breast cancer	6.76e-06	9.67e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PPARGC1B—breast cancer	6.55e-06	9.37e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—breast cancer	6.51e-06	9.31e-05	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—HMOX1—breast cancer	6.51e-06	9.31e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—COX11—breast cancer	6.47e-06	9.25e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—breast cancer	6.42e-06	9.18e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—MED12—breast cancer	6.31e-06	9.03e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—DPYD—breast cancer	6.31e-06	9.03e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—breast cancer	6.24e-06	8.93e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—breast cancer	6.22e-06	8.9e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ALDOA—breast cancer	6.22e-06	8.89e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTA4—breast cancer	6.19e-06	8.85e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CA9—breast cancer	6.19e-06	8.85e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—breast cancer	6.1e-06	8.73e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NCOA3—breast cancer	6.03e-06	8.63e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTA2—breast cancer	6.03e-06	8.62e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GPX2—breast cancer	6.03e-06	8.62e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC2A2—breast cancer	5.99e-06	8.57e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SULT1A1—breast cancer	5.95e-06	8.52e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GPX4—breast cancer	5.95e-06	8.52e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	5.93e-06	8.48e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SHMT1—breast cancer	5.91e-06	8.46e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CDA—breast cancer	5.91e-06	8.46e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ABCG2—breast cancer	5.87e-06	8.4e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—MTR—breast cancer	5.87e-06	8.4e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CPT1A—breast cancer	5.87e-06	8.4e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—IDH1—breast cancer	5.82e-06	8.32e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTA1—breast cancer	5.82e-06	8.32e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—breast cancer	5.81e-06	8.31e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—breast cancer	5.77e-06	8.25e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—HPGDS—breast cancer	5.76e-06	8.23e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NAT2—breast cancer	5.75e-06	8.23e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—HBA1—breast cancer	5.72e-06	8.18e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLCO1B1—breast cancer	5.69e-06	8.14e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC2A5—breast cancer	5.69e-06	8.14e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTT1—breast cancer	5.58e-06	7.99e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ACHE—breast cancer	5.58e-06	7.99e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—APRT—breast cancer	5.5e-06	7.86e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	5.3e-06	7.58e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP17A1—breast cancer	5.28e-06	7.56e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ENO1—breast cancer	5.23e-06	7.48e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTGS1—breast cancer	5.23e-06	7.48e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	5.21e-06	7.46e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ESRRA—breast cancer	5.17e-06	7.39e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ANGPTL4—breast cancer	5.17e-06	7.39e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—breast cancer	5.15e-06	7.36e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP2D6—breast cancer	5.13e-06	7.34e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	5.12e-06	7.33e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—MED12—breast cancer	5.04e-06	7.21e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—DPYD—breast cancer	5.04e-06	7.21e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NCOA2—breast cancer	5.04e-06	7.2e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ALDOA—breast cancer	4.96e-06	7.1e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GPI—breast cancer	4.9e-06	7.01e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—HADHB—breast cancer	4.9e-06	7.01e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—FASN—breast cancer	4.88e-06	6.99e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—BCHE—breast cancer	4.86e-06	6.96e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NCOA3—breast cancer	4.82e-06	6.89e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC5A5—breast cancer	4.8e-06	6.87e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC2A2—breast cancer	4.79e-06	6.84e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CPT1A—breast cancer	4.69e-06	6.71e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ABCG2—breast cancer	4.69e-06	6.71e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—MTR—breast cancer	4.69e-06	6.71e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ALDH1A1—breast cancer	4.68e-06	6.69e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ALDH7A1—breast cancer	4.68e-06	6.69e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—SLC2A1—breast cancer	4.64e-06	6.64e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NQO1—breast cancer	4.64e-06	6.64e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—HPGDS—breast cancer	4.6e-06	6.58e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—HBA1—breast cancer	4.57e-06	6.53e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.54e-06	6.5e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP3A4—breast cancer	4.52e-06	6.47e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.5e-06	6.44e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—FHL2—breast cancer	4.48e-06	6.41e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ADSL—breast cancer	4.48e-06	6.41e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—UMPS—breast cancer	4.48e-06	6.41e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PHGDH—breast cancer	4.48e-06	6.41e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NME1—breast cancer	4.48e-06	6.41e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ACHE—breast cancer	4.46e-06	6.38e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTT1—breast cancer	4.46e-06	6.38e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP1B1—breast cancer	4.45e-06	6.36e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—LDHB—breast cancer	4.4e-06	6.29e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—BRIP1—breast cancer	4.4e-06	6.29e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—HPSE—breast cancer	4.4e-06	6.29e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—HSP90AA1—breast cancer	4.36e-06	6.24e-05	CbGpPWpGaD
Mebendazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	4.33e-06	6.19e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NCOA1—breast cancer	4.24e-06	6.07e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP17A1—breast cancer	4.22e-06	6.04e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—STK11—breast cancer	4.18e-06	5.98e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CYP19A1—breast cancer	4.18e-06	5.98e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTGS1—breast cancer	4.18e-06	5.98e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ENO1—breast cancer	4.18e-06	5.98e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTA3—breast cancer	4.17e-06	5.96e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ABCC1—breast cancer	4.17e-06	5.96e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—HMMR—breast cancer	4.17e-06	5.96e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP2D6—breast cancer	4.1e-06	5.86e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PPARGC1B—breast cancer	4.04e-06	5.77e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NCOA2—breast cancer	4.02e-06	5.75e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.93e-06	5.62e-05	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	3.91e-06	5.59e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—FASN—breast cancer	3.9e-06	5.58e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—COMT—breast cancer	3.89e-06	5.56e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—BCHE—breast cancer	3.88e-06	5.56e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTP1—breast cancer	3.87e-06	5.54e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC5A5—breast cancer	3.84e-06	5.49e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—HMOX1—breast cancer	3.82e-06	5.46e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTA4—breast cancer	3.81e-06	5.45e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CA9—breast cancer	3.81e-06	5.45e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ITPR1—breast cancer	3.81e-06	5.45e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTA2—breast cancer	3.71e-06	5.31e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GPX2—breast cancer	3.71e-06	5.31e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NQO1—breast cancer	3.71e-06	5.3e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—SLC2A1—breast cancer	3.71e-06	5.3e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GPX4—breast cancer	3.67e-06	5.25e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SULT1A1—breast cancer	3.67e-06	5.25e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ABCB1—breast cancer	3.66e-06	5.24e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP3A4—breast cancer	3.61e-06	5.17e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—TYMS—breast cancer	3.6e-06	5.15e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTA1—breast cancer	3.58e-06	5.13e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—IDH1—breast cancer	3.58e-06	5.13e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PLA2G4A—breast cancer	3.56e-06	5.09e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NCOR1—breast cancer	3.56e-06	5.09e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GSTM1—breast cancer	3.56e-06	5.09e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP1B1—breast cancer	3.55e-06	5.08e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NAT2—breast cancer	3.54e-06	5.07e-05	CbGpPWpGaD
Mebendazole—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	3.53e-06	5.06e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—HSP90AA1—breast cancer	3.48e-06	4.98e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—GPX1—breast cancer	3.41e-06	4.87e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NCOA1—breast cancer	3.39e-06	4.85e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ERCC2—breast cancer	3.34e-06	4.78e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—STK11—breast cancer	3.34e-06	4.78e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP19A1—breast cancer	3.34e-06	4.78e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—MTHFR—breast cancer	3.14e-06	4.5e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—MED12—breast cancer	3.11e-06	4.44e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—DPYD—breast cancer	3.11e-06	4.44e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—COMT—breast cancer	3.11e-06	4.44e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTP1—breast cancer	3.09e-06	4.42e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ALDOA—breast cancer	3.06e-06	4.37e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—HMOX1—breast cancer	3.05e-06	4.36e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ITPR1—breast cancer	3.04e-06	4.35e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NCOA3—breast cancer	2.97e-06	4.25e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC2A2—breast cancer	2.95e-06	4.22e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—CAV1—breast cancer	2.9e-06	4.15e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ABCG2—breast cancer	2.89e-06	4.13e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CPT1A—breast cancer	2.89e-06	4.13e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—MTR—breast cancer	2.89e-06	4.13e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—TYMS—breast cancer	2.87e-06	4.11e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NCOR1—breast cancer	2.84e-06	4.06e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GSTM1—breast cancer	2.84e-06	4.06e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PLA2G4A—breast cancer	2.84e-06	4.06e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—HPGDS—breast cancer	2.83e-06	4.05e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—HBA1—breast cancer	2.81e-06	4.03e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.77e-06	3.96e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ACHE—breast cancer	2.75e-06	3.93e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTT1—breast cancer	2.75e-06	3.93e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—GPX1—breast cancer	2.72e-06	3.89e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CYP1A1—breast cancer	2.69e-06	3.85e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ERCC2—breast cancer	2.67e-06	3.82e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CG—breast cancer	2.64e-06	3.78e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP17A1—breast cancer	2.6e-06	3.72e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ENO1—breast cancer	2.57e-06	3.68e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTGS1—breast cancer	2.57e-06	3.68e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP2D6—breast cancer	2.52e-06	3.61e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—MTHFR—breast cancer	2.51e-06	3.59e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NCOA2—breast cancer	2.48e-06	3.54e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—FASN—breast cancer	2.4e-06	3.44e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—BCHE—breast cancer	2.39e-06	3.42e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC5A5—breast cancer	2.36e-06	3.38e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CD—breast cancer	2.32e-06	3.32e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—CAV1—breast cancer	2.32e-06	3.31e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—ALB—breast cancer	2.29e-06	3.28e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NQO1—breast cancer	2.28e-06	3.27e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—SLC2A1—breast cancer	2.28e-06	3.27e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—NOS3—breast cancer	2.19e-06	3.14e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP1B1—breast cancer	2.19e-06	3.13e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.15e-06	3.07e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CG—breast cancer	2.11e-06	3.02e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NCOA1—breast cancer	2.09e-06	2.99e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—STK11—breast cancer	2.06e-06	2.94e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP19A1—breast cancer	2.06e-06	2.94e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CB—breast cancer	2.02e-06	2.89e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTGS2—breast cancer	2e-06	2.87e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—COMT—breast cancer	1.91e-06	2.74e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTP1—breast cancer	1.9e-06	2.72e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—HMOX1—breast cancer	1.88e-06	2.69e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ITPR1—breast cancer	1.87e-06	2.68e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CD—breast cancer	1.85e-06	2.65e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—ALB—breast cancer	1.83e-06	2.62e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ABCB1—breast cancer	1.8e-06	2.58e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—TYMS—breast cancer	1.77e-06	2.53e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—NOS3—breast cancer	1.75e-06	2.5e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NCOR1—breast cancer	1.75e-06	2.5e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.75e-06	2.5e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GSTM1—breast cancer	1.75e-06	2.5e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PTEN—breast cancer	1.75e-06	2.5e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—GPX1—breast cancer	1.68e-06	2.4e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CYP1A1—breast cancer	1.66e-06	2.37e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ERCC2—breast cancer	1.65e-06	2.35e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CB—breast cancer	1.62e-06	2.31e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTGS2—breast cancer	1.6e-06	2.29e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—MTHFR—breast cancer	1.55e-06	2.21e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—CAV1—breast cancer	1.43e-06	2.04e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PTEN—breast cancer	1.4e-06	2e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CG—breast cancer	1.3e-06	1.86e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—PIK3CA—breast cancer	1.23e-06	1.76e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CD—breast cancer	1.14e-06	1.63e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—ALB—breast cancer	1.13e-06	1.61e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—NOS3—breast cancer	1.08e-06	1.54e-05	CbGpPWpGaD
Mebendazole—CYP1A1—Metabolism—AKT1—breast cancer	1.01e-06	1.44e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CB—breast cancer	9.96e-07	1.42e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTGS2—breast cancer	9.87e-07	1.41e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—PIK3CA—breast cancer	9.85e-07	1.41e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PTEN—breast cancer	8.6e-07	1.23e-05	CbGpPWpGaD
Mebendazole—ABCB1—Metabolism—AKT1—breast cancer	8.05e-07	1.15e-05	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—PIK3CA—breast cancer	6.07e-07	8.68e-06	CbGpPWpGaD
Mebendazole—CYP3A4—Metabolism—AKT1—breast cancer	4.96e-07	7.09e-06	CbGpPWpGaD
